Gilead’s $7.8B Arcellx buy isn’t just M&A. It’s an “option exercise” on CAR-T: pay up to own the flywheel—manufacturing, label expansion, and the economics of scale.
https://biotech.industryexaminer.com/gilead-arcellx-78b-car-t-option-exercise-anito-cel/
#Biotech #CellTherapy #CART #Oncology #MergersAndAcquisitions #MultipleMyeloma




